相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
Keith W. Pratz et al.
BLOOD (2009)
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3
Seiji Fukuda et al.
BLOOD (2009)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Marcus M. Schittenhelm et al.
CELL CYCLE (2009)
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
Ellen Weisberg et al.
BLOOD (2008)
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Lars Bullinger et al.
BLOOD (2008)
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells
Ellen Weisberg et al.
BLOOD (2008)
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication
Adam J. Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A phase I trial of CEP-701+gemcitabine in patients with advanced adenocarcinoma of the pancreas
Emily Chan et al.
INVESTIGATIONAL NEW DRUGS (2008)
Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment
U. Mony et al.
LEUKEMIA (2008)
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
Chie Nishioka et al.
LEUKEMIA RESEARCH (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Lars Mollgard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
T. M. Kohl et al.
LEUKEMIA (2007)
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Ellen Weisberg et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics:: are we ready for a prognostically prioritized molecular classification?
Krzysztof Mrozek et al.
BLOOD (2007)
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells
Li Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Steven Knapper et al.
BLOOD (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
Steven M. Kornblau et al.
BLOOD (2006)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression
P Brown et al.
BLOOD (2005)
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
JL Marshall et al.
INVESTIGATIONAL NEW DRUGS (2005)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
MG Mohi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
KF Tse et al.
LEUKEMIA (2000)
分享论文
